Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) EBIT Margin (2022 - 2025)

Bioregenx has reported EBIT Margin over the past 4 years, most recently at 242.62% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 373506.0% year-over-year to 242.62%; the TTM value through Dec 2025 reached 67.08%, up 90567.0%, while the annual FY2025 figure was 67.08%, 90567.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 242.62% at Bioregenx, down from 1.67% in the prior quarter.
  • Over five years, EBIT Margin peaked at 1.67% in Q3 2025 and troughed at 3977.69% in Q4 2024.
  • A 4-year average of 391.27% and a median of 61.89% in 2022 define the central range for EBIT Margin.
  • Biggest five-year swings in EBIT Margin: crashed -394649bps in 2024 and later soared 373506bps in 2025.
  • Year by year, EBIT Margin stood at 62.09% in 2022, then soared by 50bps to 31.2% in 2023, then crashed by -12648bps to 3977.69% in 2024, then soared by 94bps to 242.62% in 2025.
  • Business Quant data shows EBIT Margin for BRGX at 242.62% in Q4 2025, 1.67% in Q3 2025, and 24.05% in Q2 2025.